Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carteolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 0.98 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 4/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carteolol SCHEMBL41382 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL29506901 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL30872857 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL24810 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL29908301 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL24811 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL146637 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL2549082 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL26664799 | 0.98 | ADRB1 (0.98) | ADRB2ADRB1HTR1AOPRK1ADRB3 | |
| Carteolol SCHEMBL26664802 | 0.98 | ADRB1 (0.98) | ADRB2ADRB1HTR1AOPRK1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3161 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2026-01-29 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| EP-4527387-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2025-03-26 | — | — | EP | claimed |
| CN-119405621-A | Drug-loaded polyacrylic resin nanoparticle as well as preparation method and application thereof | 广东药科大学 | 2025-02-11 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-114796219-B | Compound pharmaceutical composition for treating glaucoma and application thereof | 沈阳药科大学 | 2024-08-20 | — | — | CN | claimed |
| CN-118490691-A | Use of adenosine A2A receptor antagonists in the treatment and prevention of glaucoma | 温州医科大学附属眼视光医院 | 2024-08-16 | — | — | CN | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| WO-2023221852-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | 沈阳药科大学 | 2023-11-23 | — | — | WO | claimed |
| EP-0347987-A2 | Tripeptide renin inhibitors with N-terminal carbamoyl or acyl groups | MERCK & CO. INC. (US) | 1989-12-27 | — | — | EP | claimed |
| EP-0314239-A2 | Tripeptide renin inhibitors with N-terminal ureido or sulfamido groups | MERCK & CO. INC. (US) | 1989-05-03 | — | — | EP | claimed |
| EP-0312291-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0312158-A2 | Tetrapeptide renin inhibitors having novel c-terminal amino acid amide | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0312283-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restrictions in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0312157-A2 | Tetrapeptide renin inhibitors having a novel c-terminal amino acid | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| US-4782043-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | claimed |
| EP-0278158-A2 | Renin inhibitors containing phenylalanyl-histidine replacements | MERCK & CO. INC. (US) | 1988-08-17 | — | — | EP | claimed |
| EP-0273696-A2 | Renin inhibitors containing histidine replacements | MERCK & CO. INC. (US) | 1988-07-06 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |